期刊
DRUG DISCOVERY TODAY
卷 17, 期 7-8, 页码 367-378出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.10.028
关键词
-
资金
- European Commission [PITN-GA-2010-264506 NanoTOES]
Injectable nanosized carriers (5-250 nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据